CBD shows promise for schizophrenia in new trial
NCT ID NCT02926859
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether cannabidiol (CBD) capsules, added to standard antipsychotic medication, can help people with early schizophrenia recover better and stay on treatment longer. 180 participants receive either CBD or placebo for 26 weeks. The goal is to see if CBD improves symptoms and reduces side effects like weight gain and movement problems.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cannabidiol (CBD) capsules
What this could lead to
If successful, this could point toward a safer, better-tolerated add-on treatment for schizophrenia that helps patients stay on therapy longer.
What could go wrong
This is a mid-stage trial with 180 participants, so results may not apply to all patients. CBD may not outperform placebo, and long-term safety is still unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dep. of Psychiatry and Psychotherapy, Central Institute of Mental Health
Mannheim, Baden-Wurttemberg, 68159, Germany
-
Department of Psychiatry und Psychotherapy, University Hospital Hamburg-Eppendorf
Hamburg, 20246, Germany
-
Department of Psychiatry, Psychotherapy, and Psychosomatics, RWTH Aachen
Aachen, North Rhine-Westphalia, 52074, Germany
-
Dept. of Psychiatry and Psychotherapy, Charité, Campus Charité-Mitte
Berlin, B, 10117, Germany
-
Dept. of Psychiatry and Psychotherapy, Ludwig-Maximillians-University Munich
Munich, Bavaria, 80336, Germany
-
Dept. of Psychiatry and Psychotherapy, University Hospital of Cologne
Cologne, North Rhine-Westphalia, 50924, Germany